Abstract
It has been proposed that the onset of Acquired Thrombotic Thrombocytopenic Purpura (iTTP) is more severe than subsequent relapses; however, existing studies have limitations. We conducted a retrospective observational study to compare analytical and clinical severity of onset and relapse aTTP cases between 2012 and 2023. A total of 370 episodes of aTTP were analyzed, comprising 272 at initial diagnosis and 98 relapses. At onset, analytical parameters indicative of severity (low hemoglobin, low platelet count, and increased LDH) were significantly worse; patients had severe neurological symptoms (p<0.001) and ≥ 3 points in the TMA mortality score (p<0.001). In conclusion, the onset of aTTP is associated with worse analytical parameters and severe neurological involvement.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
No datasets were generated or analysed during the current study.
References
Domingo-González A, Regalado-Artamendi I, Martín-Rojas RM, Pérez-Rus G, Pérez-Corral A, Díez-Martín JL et al (2021) Application of the French TMA Reference Center Score and the mortality in TTP score in de novo and relapsed episodes of acquired thrombotic thrombocytopenic purpura at a tertiary care facility in Spain. J Clin Apher 36(3):420–428
Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2017) Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 1(10):590–600
Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A et al (2010) Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 151(5):488–494
Alvarez-Larrán A, Río-Garma J, Pujol M, Rubia J, Hernández-Jodra M, Borrell M et al (2009) Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. Ann Hematol 88(10):973–978
Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S et al (2017) Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 130(4):466–471
Masias C, Wu H, McGookey M, Jay L, Cataland S, Yang S (2018) No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry. Vol. 93, American Journal of Hematology. Wiley-Liss Inc. p. E73–5
Benhamou Y, Assié C, Boelle PY, Buffet M, Grillberger R, Malot S et al (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97(8):1181–1186
Chiasakul T, Cuker A (2018) Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology Am Soc Hematol Educ Program 2018(1):530–538. https://doi.org/10.1182/asheducation-2018.1.530
Author information
Authors and Affiliations
Contributions
BVV and RCE contributed equally to the design of the study, data collection, statistical analysis, writing, and critical revision of the final manuscript being both first authors. SMM, MCS, IAM, MMP, BSL, YRR, JCM, PEM, PRG, SFB, MPMH, FAGF, MGA, AVM, CBC, and JMN contributed to the data collection, sample analysis, and critical revision of the final manuscript. Also, all authors contributed to a literature review on the topic.
Corresponding author
Ethics declarations
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Vegas Villalmanzo, B., Cantera Estefanía, R., Muñoz Madrid, S. et al. Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut. Ann Hematol 103, 725–727 (2024). https://doi.org/10.1007/s00277-024-05634-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-024-05634-x